Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Given Average Recommendation of “Moderate Buy” by Analysts

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $9.12.

AUTL has been the subject of a number of research analyst reports. Wells Fargo & Company reduced their price target on shares of Autolus Therapeutics from $6.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, July 21st. Wall Street Zen upgraded shares of Autolus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Saturday, September 27th.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Marex Group plc acquired a new stake in shares of Autolus Therapeutics during the second quarter valued at approximately $28,000. Bank of America Corp DE raised its holdings in shares of Autolus Therapeutics by 2,891.7% during the second quarter. Bank of America Corp DE now owns 975,135 shares of the company’s stock valued at $2,223,000 after acquiring an additional 942,540 shares during the period. Armistice Capital LLC raised its holdings in shares of Autolus Therapeutics by 9.1% during the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company’s stock valued at $27,360,000 after acquiring an additional 1,000,000 shares during the period. TFG Asset Management GP Ltd raised its holdings in shares of Autolus Therapeutics by 10.5% during the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company’s stock valued at $21,660,000 after acquiring an additional 900,000 shares during the period. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Autolus Therapeutics by 41.6% during the second quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after acquiring an additional 11,289 shares during the period. 72.83% of the stock is currently owned by institutional investors.

Autolus Therapeutics Stock Performance

Shares of NASDAQ:AUTL opened at $1.61 on Friday. The company has a 50 day moving average of $1.74 and a 200-day moving average of $1.78. The firm has a market cap of $428.49 million, a P/E ratio of -1.92 and a beta of 1.84. Autolus Therapeutics has a twelve month low of $1.11 and a twelve month high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. The company had revenue of $13.50 million during the quarter, compared to analyst estimates of $12.92 million. Equities research analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.